PT  - JOURNAL ARTICLE
AU  - S. Moein Moghimi
AU  - Dmitri Simberg
AU  - Tore Skotland
AU  - Anan Yaghmur
AU  - A. Christy Hunter
TI  - The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses
AID  - 10.1124/jpet.119.258012
DP  - 2019 Sep 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 581--592
VI  - 370
IP  - 3
4099  - http://jpet.aspetjournals.org/content/370/3/581.short
4100  - http://jpet.aspetjournals.org/content/370/3/581.full
SO  - J Pharmacol Exp Ther2019 Sep 01; 370
AB  - In the blood, depending on their physicochemical characteristics, nanoparticles attract a wide range of plasma biomolecules. The majority of blood biomolecules bind nonspecifically to nanoparticles. On the other hand, biomolecules such as pattern-recognition complement-sensing proteins may recognize some structural determinants of the pristine surface, causing complement activation. Adsorption of nonspecific blood proteins could also recruit natural antibodies and initiate complement activation, and this seems to be a global process with many preclinical and clinical nanomedicines. We discuss these issues, since complement activation has ramifications in nanomedicine stability and pharmacokinetics, as well as in inflammation and disease progression. Some studies have also predicted a role for complement systems in infusion-related reactions, whereas others show a direct role for macrophages and other immune cells independent of complement activation. We comment on these discrepancies and suggest directions for exploring the underlying mechanisms.